Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Research & Development for 10 years, with the latest figure at $27.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 61.62% year-over-year to $27.5 million; the trailing twelve-month figure through Mar 2026 stood at $105.0 million (up 2.65% YoY), and the FY2025 full-year result was $96.9 million, down 13.23% from the prior year.
• Research & Development for Q1 2026 stood at $27.5 million, down from $34.6 million in the prior quarter.
• The five-year high for Research & Development was $35.2 million in Q4 2024, with the low at $13.8 million in Q2 2022.
• Historically, Research & Development has averaged $22.1 million across 5 years, with a median of $20.8 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development sank 47.54% — and 2024, when it jumped 75.62%.
• Kiniksa Pharmaceuticals International's Research & Development stood at $14.4 million in 2022, then soared by 39.35% to $20.1 million in 2023, then surged by 75.62% to $35.2 million in 2024, then fell by 1.72% to $34.6 million in 2025, then fell by 20.61% to $27.5 million in 2026.
• The last three Research & Development figures came in at $27.5 million (Q1 2026), $34.6 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.